4//SEC Filing
Cabell Christopher 4
Accession 0001209191-20-042910
CIK 0001080709other
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 5:23 PM ET
Size
8.9 KB
Accession
0001209191-20-042910
Insider Transaction Report
Form 4
Cabell Christopher
EVP, Head of R&D, and CMO
Transactions
- Exercise/Conversion
Common Stock
2020-07-15$26.28/sh+13,000$341,640→ 13,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2020-07-15−13,000→ 47,000 totalExercise: $26.28Exp: 2024-11-15→ Common Stock (13,000 underlying) - Sale
Common Stock
2020-07-15$68.00/sh−13,000$884,000→ 0 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
- [F2]The options vest over four years, with 25% of the shares subject to the option vesting on November 15, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
Documents
Issuer
ARENA PHARMACEUTICALS INC
CIK 0001080709
Entity typeother
Related Parties
1- filerCIK 0001814928
Filing Metadata
- Form type
- 4
- Filed
- Jul 16, 8:00 PM ET
- Accepted
- Jul 17, 5:23 PM ET
- Size
- 8.9 KB